We are live on
!
Find out more
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
(-7.6%)
Cap. Flow
+$275M
Cap. Flow
% of AUM
2.78%
Top 10 Holdings %
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24
Avg Time Held Equity + Options
1.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
1.6
years
Avg Time Held Equity only
1.7
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$123M |
| 2 |
Neuropace
NPCE
|
+$93.1M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$77.8M |
| 4 |
Janux Therapeutics
JANX
|
+$77.2M |
| 5 |
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$74.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$94.6M |
| 2 |
AbCellera Biologics
ABCL
|
+$54.5M |
| 3 |
Adverum Biotechnologies
ADVM
|
+$54.2M |
| 4 |
Molina Healthcare
MOH
|
+$38M |
| 5 |
PAND
Pandion Therapeutics Inc. Common Stock
PAND
|
+$31.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.72% |
| 2 | Miscellaneous | 4.15% |
| 3 | Technology | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
NMTR
126
DELISTED
9 Meters Biopharma
NMTR
| $9.42M | 0.1% |
428,299
-857,539
| -67% | -$21.1M |
2020 Q2
4 quarters
|
|
127
NovaBridge Biosciences American Depositary Shares
NBP
$151M
| $9.33M | 0.09% |
111,120
+92,555
| +499% | +$6.11M |
2020 Q3
3 quarters
|
|
128
Gyre Therapeutics
GYRE
$704M
| $9.17M | 0.09% |
282,480
| – | – |
2021 Q1
1 quarter
|
|
129
X4 Pharmaceuticals
XFOR
$258M
| $8.93M | 0.09% |
45,795
| – | – |
2017 Q4
14 quarters
|
|
130
Whitehawk Therapeutics
WHWK
$176M
| $8.78M | 0.09% |
346,263
| – | – |
2018 Q2
12 quarters
|
|
|
ASLN
131
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $8.32M | 0.08% |
63,000
| – | – |
2021 Q1
1 quarter
|
|
132
ALX Oncology
ALXO
$123M
| $8.2M | 0.08% |
150,000
| – | – |
2020 Q4
2 quarters
|
|
133
Sutro Biopharma
STRO
$191M
| $8.06M | 0.08% |
43,370
+8,370
| +24% | +$1.64M |
2020 Q4
2 quarters
|
|
134
Nurix Therapeutics
NRIX
$2.72B
| $7.96M | 0.08% |
300,000
| – | – |
2020 Q3
3 quarters
|
|
135
Monte Rosa Therapeutics
GLUE
$867M
| $7.95M | 0.08% |
+350,000
| New | +$7.13M |
2021 Q2
0 quarters
|
|
136
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| $7.87M | 0.08% |
68,100
| – | – |
2021 Q1
1 quarter
|
|
137
Dyne Therapeutics
DYN
$2.87B
| $7.36M | 0.07% |
350,000
| – | – |
2020 Q3
3 quarters
|
|
|
OTIC
138
DELISTED
Otonomy, Inc.
OTIC
| $7.25M | 0.07% |
3,250,000
| – | – |
2020 Q3
3 quarters
|
|
139
Nanobiotix
NBTX
$1.11B
| $6.89M | 0.07% |
500,000
| – | – |
2020 Q4
2 quarters
|
|
140
Aclaris Therapeutics
ACRS
$512M
| $6.36M | 0.06% |
+362,000
| New | +$8.22M |
2021 Q2
0 quarters
|
|
|
RXDX
141
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $6.14M | 0.06% |
250,000
| – | – |
2021 Q1
1 quarter
|
|
142
DELISTED
Verve Therapeutics
VERV
| $6.03M | 0.06% |
+100,000
| New | +$4.15M |
2021 Q2
0 quarters
|
|
143
Pulmonx
LUNG
$77.7M
| $5.51M | 0.06% |
125,000
| – | – |
2020 Q4
2 quarters
|
|
|
SBBP
144
DELISTED
Strongbridge Biopharma plc.
SBBP
| $5.18M | 0.05% |
1,744,669
| – | – |
2020 Q3
3 quarters
|
|
145
Orchestra BioMed
OBIO
$350M
| $5.1M | 0.05% |
500,000
| – | – |
2020 Q3
3 quarters
|
|
146
Organon & Co
OGN
$3.61B
| $5.05M | 0.05% |
+166,939
| New | +$5.5M |
2021 Q2
0 quarters
|
|
147
Sarepta Therapeutics
SRPT
$1.88B
| $5.03M | 0.05% |
64,700
-135,578
| -68% | -$10.3M |
2017 Q4
14 quarters
|
|
148
Protara Therapeutics
TARA
$148M
| $4.38M | 0.04% |
450,000
| – | – |
2020 Q3
3 quarters
|
|
149
Adagene
ADAG
$159M
| $3.73M | 0.04% |
275,000
| – | – |
2021 Q1
1 quarter
|
|
150
DELISTED
Tourmaline Bio
TRML
| $3.63M | 0.04% |
+24,724
| New | +$3.79M |
2021 Q2
0 quarters
|
|
Similar funds
OrbiMed's Q2 2021 Portfolio in Review
As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.
- OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
- OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
- OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
- OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
- OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
- OrbiMed opened 24 new positions and closed 24 in Q2 2021.
- OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.
Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.